Mesoblast Ltd ADR (MESO)

$14.82 -0.55 (-3.58%)
Market Cap 1.90B
Revenue (ttm) 17.20M
Net Income (ttm) -102.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -593.84%
Debt to Equity Ratio 0.20
Volume 185,700
Avg Vol 244,240
Day's Range N/A - N/A
Shares Out 128.00M
Stochastic %K 72%
Beta 2.26
Analysts Strong Sell
Price Target $27.00

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
Address:
55 Collins Street, Level 38, Melbourne, Australia
hots
hots Sep. 12 at 10:14 AM
$MESO We need to stop obsessing over sales numbers. The CEO subtly stated they treated two kids without insurance as it was the right thing to do. The value will come over time , regardless if one quarters numbers are below expectations. The true value is in the many extensions and that is likely why he doesn’t provide sales guidance. If you build it the value with come. Good luck to all holders
0 · Reply
Mani86
Mani86 Sep. 11 at 2:11 AM
$MESO Expecting good sales number in coming quarters given more hospitals have onboarded with Ryoncil. Board members buying actively in the market is always a good sign 👍
0 · Reply
zipperson
zipperson Sep. 10 at 8:27 PM
$MESO Nice close!
0 · Reply
zipperson
zipperson Sep. 10 at 4:01 PM
$MESO I won’t be surprised if we hit $20 in a month.
0 · Reply
zipperson
zipperson Sep. 10 at 3:58 PM
$MESO https://www.tipranks.com/news/ratings/buy-rating-for-mesoblast-driven-by-strong-ryoncil-launch-and-strategic-financial-moves-ratings
0 · Reply
zipperson
zipperson Sep. 9 at 5:45 PM
$MESO Breaking out imminent!
0 · Reply
zipperson
zipperson Sep. 9 at 3:52 AM
$MESO FDA Approval & Commercial Launch of Ryoncil® • Mesoblast achieved a significant milestone in FY 2025 by obtaining FDA approval for Ryoncil® (remestemcel-L), the first MSC therapy cleared for steroid-refractory acute GvHD in pediatric patients. • The product’s commercial debut saw strong uptake: $11.3 million in net sales during the first quarter, contributing to a full fiscal year product revenue of $17.2 million, up 191% year-over-year.  • The company now covers over 250 million U.S. lives, has on-boarded 32 transplant centers, and holds orphan drug exclusivity through 2032 plus biologic exclusivity through 2036.
2 · Reply
Mani86
Mani86 Sep. 6 at 2:14 AM
$MESO https://insightfinancenews.com/commercial-launch-of-ryoncil/ Article from July 25 but summarises the companies plans.
0 · Reply
zipperson
zipperson Sep. 5 at 1:18 PM
$MESO
0 · Reply
zipperson
zipperson Sep. 4 at 11:38 PM
$MESO
1 · Reply
Latest News on MESO
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Sep 3, 2025, 9:47 PM EDT - 10 days ago

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

Aug 29, 2025, 12:27 PM EDT - 16 days ago

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Aug 28, 2025, 8:24 PM EDT - 16 days ago

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Successful Commercial Launch of Ryoncil®

Jul 17, 2025, 8:38 PM EDT - 2 months ago

Successful Commercial Launch of Ryoncil®

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Jul 1, 2025, 8:46 AM EDT - 2 months ago

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Jun 30, 2025, 8:36 PM EDT - 2 months ago

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Jun 11, 2025, 9:24 PM EDT - 3 months ago

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

May 14, 2025, 10:57 PM EDT - 4 months ago

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

May 5, 2025, 2:44 AM EDT - 4 months ago

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Apr 29, 2025, 8:53 PM EDT - 4 months ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Apr 28, 2025, 7:44 PM EDT - 4 months ago

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Apr 16, 2025, 9:20 PM EDT - 5 months ago

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Apr 3, 2025, 6:58 PM EDT - 5 months ago

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Apr 2, 2025, 7:15 PM EDT - 5 months ago

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

First Three Children to Commence Treatment With Ryoncil®

Mar 30, 2025, 7:39 PM EDT - 5 months ago

First Three Children to Commence Treatment With Ryoncil®

Ryoncil® is Now Available for Purchase in the United States

Mar 26, 2025, 8:19 PM EDT - 6 months ago

Ryoncil® is Now Available for Purchase in the United States

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mar 13, 2025, 7:42 PM EDT - 6 months ago

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mar 12, 2025, 7:30 AM EDT - 6 months ago

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Feb 28, 2025, 11:38 AM EST - 7 months ago

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Feb 26, 2025, 5:30 PM EST - 7 months ago

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Mesoblast Financial Results and Corporate Update Webcast

Feb 25, 2025, 6:13 PM EST - 7 months ago

Mesoblast Financial Results and Corporate Update Webcast

Dr. Gregory George MD PhD Joins Mesoblast Board

Feb 23, 2025, 6:33 PM EST - 7 months ago

Dr. Gregory George MD PhD Joins Mesoblast Board

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Feb 13, 2025, 6:37 PM EST - 7 months ago

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Ryoncil® Commercial Launch Update and Product Pipeline

Jan 30, 2025, 7:11 PM EST - 8 months ago

Ryoncil® Commercial Launch Update and Product Pipeline

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Jan 30, 2025, 6:20 PM EST - 8 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Dec 19, 2024, 6:38 AM EST - 9 months ago

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

Dec 18, 2024, 7:08 PM EST - 9 months ago

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Dec 18, 2024, 4:58 PM EST - 9 months ago

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Mesoblast to be Added to Nasdaq Biotechnology Index

Dec 18, 2024, 7:30 AM EST - 9 months ago

Mesoblast to be Added to Nasdaq Biotechnology Index

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Dec 12, 2024, 12:08 PM EST - 9 months ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

CAPR XBI

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Dec 4, 2024, 6:32 PM EST - 10 months ago

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Dec 2, 2024, 6:20 PM EST - 10 months ago

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Oct 30, 2024, 7:11 PM EDT - 11 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30, 2024, 4:24 PM EDT - 1 year ago

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Sep 29, 2024, 8:55 PM EDT - 1 year ago

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Aug 28, 2024, 9:04 PM EDT - 1 year ago

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Aug 28, 2024, 7:27 PM EDT - 1 year ago

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

Jul 30, 2024, 9:13 PM EDT - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jul 23, 2024, 7:53 AM EDT - 1 year ago

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Jul 21, 2024, 8:45 PM EDT - 1 year ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jul 8, 2024, 8:37 PM EDT - 1 year ago

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Jul 1, 2024, 1:55 AM EDT - 1 year ago

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Mesoblast Corporate Presentation at Investor Conference

Jun 2, 2024, 8:23 PM EDT - 1 year ago

Mesoblast Corporate Presentation at Investor Conference

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

Apr 29, 2024, 9:05 PM EDT - 1 year ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mar 25, 2024, 10:34 PM EDT - 1 year ago

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

Mar 13, 2024, 7:30 PM EDT - 1 year ago

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Mar 10, 2024, 7:54 PM EDT - 1 year ago

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript

Feb 29, 2024, 6:07 PM EST - 1 year ago

Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Feb 28, 2024, 5:57 PM EST - 1 year ago

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Feb 14, 2024, 7:46 PM EST - 1 year ago

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

hots
hots Sep. 12 at 10:14 AM
$MESO We need to stop obsessing over sales numbers. The CEO subtly stated they treated two kids without insurance as it was the right thing to do. The value will come over time , regardless if one quarters numbers are below expectations. The true value is in the many extensions and that is likely why he doesn’t provide sales guidance. If you build it the value with come. Good luck to all holders
0 · Reply
Mani86
Mani86 Sep. 11 at 2:11 AM
$MESO Expecting good sales number in coming quarters given more hospitals have onboarded with Ryoncil. Board members buying actively in the market is always a good sign 👍
0 · Reply
zipperson
zipperson Sep. 10 at 8:27 PM
$MESO Nice close!
0 · Reply
zipperson
zipperson Sep. 10 at 4:01 PM
$MESO I won’t be surprised if we hit $20 in a month.
0 · Reply
zipperson
zipperson Sep. 10 at 3:58 PM
$MESO https://www.tipranks.com/news/ratings/buy-rating-for-mesoblast-driven-by-strong-ryoncil-launch-and-strategic-financial-moves-ratings
0 · Reply
zipperson
zipperson Sep. 9 at 5:45 PM
$MESO Breaking out imminent!
0 · Reply
zipperson
zipperson Sep. 9 at 3:52 AM
$MESO FDA Approval & Commercial Launch of Ryoncil® • Mesoblast achieved a significant milestone in FY 2025 by obtaining FDA approval for Ryoncil® (remestemcel-L), the first MSC therapy cleared for steroid-refractory acute GvHD in pediatric patients. • The product’s commercial debut saw strong uptake: $11.3 million in net sales during the first quarter, contributing to a full fiscal year product revenue of $17.2 million, up 191% year-over-year.  • The company now covers over 250 million U.S. lives, has on-boarded 32 transplant centers, and holds orphan drug exclusivity through 2032 plus biologic exclusivity through 2036.
2 · Reply
Mani86
Mani86 Sep. 6 at 2:14 AM
$MESO https://insightfinancenews.com/commercial-launch-of-ryoncil/ Article from July 25 but summarises the companies plans.
0 · Reply
zipperson
zipperson Sep. 5 at 1:18 PM
$MESO
0 · Reply
zipperson
zipperson Sep. 4 at 11:38 PM
$MESO
1 · Reply
Mani86
Mani86 Sep. 4 at 12:24 PM
$MESO The biggest shareholder Gregory George and company have entered into agreement with mesoblast for financing 50 million dollars through warrants at 16.25 dollars per ADR. This is a screaming buy at these levels as the potential is huge, market will wake up soon.
1 · Reply
zipperson
zipperson Sep. 3 at 9:34 PM
$MESO Robinhood can’t filled; so much manipulation.
0 · Reply
zipperson
zipperson Sep. 3 at 3:22 PM
$MESO Outlook and Positioning for Next Quarter (Q1 FY2026): Analysts expect continued momentum, with revenue forecasted at $23.2 million for the next quarter (a notable increase from the prior quarter’s $14.1 million) and EPS at -$0.24.   This suggests MESO is gearing up for growth through its pipeline advancements, such as potential regulatory approvals and expanded commercialization of therapies like Remestemcel-L and Rexlemestrocel-L. The company’s ample cash reserves support ongoing clinical trials and operations, positioning it well to manage expected losses while pursuing revenue expansion.   Longer-term, earnings and revenue are projected to grow at over 45% annually, with a consensus “Buy” rating and average price target of $18.00.  
0 · Reply
zipperson
zipperson Aug. 30 at 12:09 PM
$MESO revenue has grown from $3M to $14M, an increase of more than 4.5x. With additional drugs in the pipeline, I expect continued growth ahead. The company has also made significant spending reductions as it shifts focus toward manufacturing. MESO is now aligned for profitability and growth heading into 2026, making this an ideal time to accumulate.
1 · Reply
DCRMIA
DCRMIA Aug. 29 at 5:30 PM
$MESO Super bullish! It bounced off the 50-day moving average. Let's go!🚀🚀🚀
0 · Reply
zipperson
zipperson Aug. 29 at 2:56 PM
$MESO +10K and counting!
0 · Reply
zipperson
zipperson Aug. 29 at 1:48 PM
$MESO Puts price tells me it’s a manipulation. No one wants it.
0 · Reply
zipperson
zipperson Aug. 29 at 1:42 PM
$MESO Wow! Easily 10% from here.
1 · Reply
zipperson
zipperson Aug. 29 at 1:35 PM
$MESO • A Turning Point: The FDA’s approval and initial commercial launch of Ryoncil marks a major milestone—transitioning MESO into a revenue-generating biotech. • Revenue Trajectory: While very early, forecasts point toward a ramp from $12–35 M in the near term to potentially $150 M+ over time if expansions succeed. • Pipeline Depth: Multiple RMAT-endorsed candidates (heart failure, back pain, adult indications) suggest substantial future upside. • Financial Discipline: Strong cost containment, manufacturing scaling post-launch, and prudent capital raises have positioned the company with runway to execute.
0 · Reply
zipperson
zipperson Aug. 29 at 1:24 PM
$MESO Mesoblast cites multi-billion-dollar opportunities: • ~$1 B for SR-aGVHD • $5+ B for IBD • $10+ B each for heart failure and chronic back pain
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 29 at 12:52 PM
$MESO (-10.3% pre) Mesoblast Limited Reports 2025 Earnings and Strategic Outlook https://ooc.bz/l/75698
0 · Reply
zipperson
zipperson Aug. 29 at 11:56 AM
$MESO new drugs in the pipeline…more revenue. It’s loading time.
0 · Reply